nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABL1—liver cancer	0.181	0.54	CbGaD
Ponatinib—KDR—liver cancer	0.154	0.459	CbGaD
Ponatinib—FGFR1—Sorafenib—liver cancer	0.0784	0.179	CbGbCtD
Ponatinib—FLT3—Sorafenib—liver cancer	0.0677	0.155	CbGbCtD
Ponatinib—KDR—Sorafenib—liver cancer	0.0677	0.155	CbGbCtD
Ponatinib—RET—Sorafenib—liver cancer	0.0677	0.155	CbGbCtD
Ponatinib—KIT—Sorafenib—liver cancer	0.0538	0.123	CbGbCtD
Ponatinib—PDGFRA—Sorafenib—liver cancer	0.0538	0.123	CbGbCtD
Ponatinib—ABCB11—bile canaliculus—liver cancer	0.0189	0.388	CbGeAlD
Ponatinib—ABCB11—Doxorubicin—liver cancer	0.0113	0.0259	CbGbCtD
Ponatinib—ABCG2—Sorafenib—liver cancer	0.00889	0.0203	CbGbCtD
Ponatinib—ABCB11—bile duct—liver cancer	0.00591	0.121	CbGeAlD
Ponatinib—ABCG2—Doxorubicin—liver cancer	0.00539	0.0123	CbGbCtD
Ponatinib—CYP3A5—Sorafenib—liver cancer	0.00492	0.0113	CbGbCtD
Ponatinib—CYP2C8—Sorafenib—liver cancer	0.00473	0.0108	CbGbCtD
Ponatinib—ABCB11—bile—liver cancer	0.00454	0.0931	CbGeAlD
Ponatinib—ABCB1—Sorafenib—liver cancer	0.0032	0.00732	CbGbCtD
Ponatinib—CYP2D6—Sorafenib—liver cancer	0.00302	0.0069	CbGbCtD
Ponatinib—KDR—umbilical vein—liver cancer	0.00233	0.0479	CbGeAlD
Ponatinib—ABCB1—Doxorubicin—liver cancer	0.00194	0.00444	CbGbCtD
Ponatinib—CYP3A4—Sorafenib—liver cancer	0.00192	0.00439	CbGbCtD
Ponatinib—CYP2D6—Doxorubicin—liver cancer	0.00183	0.00419	CbGbCtD
Ponatinib—FGFR4—embryo—liver cancer	0.00174	0.0357	CbGeAlD
Ponatinib—FGFR3—embryo—liver cancer	0.00119	0.0244	CbGeAlD
Ponatinib—CYP3A4—Doxorubicin—liver cancer	0.00116	0.00266	CbGbCtD
Ponatinib—PDGFRA—gall bladder—liver cancer	0.00106	0.0218	CbGeAlD
Ponatinib—Nilotinib—MAPK8—liver cancer	0.00104	0.287	CrCbGaD
Ponatinib—Nilotinib—MAPK14—liver cancer	0.001	0.277	CrCbGaD
Ponatinib—KIT—gall bladder—liver cancer	0.000851	0.0175	CbGeAlD
Ponatinib—RET—embryo—liver cancer	0.000818	0.0168	CbGeAlD
Ponatinib—FGFR4—liver—liver cancer	0.000804	0.0165	CbGeAlD
Ponatinib—FGFR2—embryo—liver cancer	0.000777	0.0159	CbGeAlD
Ponatinib—TEK—embryo—liver cancer	0.000745	0.0153	CbGeAlD
Ponatinib—PDGFRA—embryo—liver cancer	0.000675	0.0138	CbGeAlD
Ponatinib—SRC—embryo—liver cancer	0.000662	0.0136	CbGeAlD
Ponatinib—KDR—embryo—liver cancer	0.000609	0.0125	CbGeAlD
Ponatinib—LYN—liver—liver cancer	0.000552	0.0113	CbGeAlD
Ponatinib—FGFR3—liver—liver cancer	0.000549	0.0113	CbGeAlD
Ponatinib—KIT—embryo—liver cancer	0.000539	0.0111	CbGeAlD
Ponatinib—Nilotinib—BRAF—liver cancer	0.000528	0.146	CrCbGaD
Ponatinib—Nilotinib—ABL1—liver cancer	0.000528	0.146	CrCbGaD
Ponatinib—BCR—liver—liver cancer	0.000475	0.00975	CbGeAlD
Ponatinib—FLT3—liver—liver cancer	0.000472	0.00968	CbGeAlD
Ponatinib—ABL1—embryo—liver cancer	0.00047	0.00964	CbGeAlD
Ponatinib—Imatinib—ABL1—liver cancer	0.00044	0.121	CrCbGaD
Ponatinib—FGFR1—liver—liver cancer	0.000423	0.00867	CbGeAlD
Ponatinib—LCK—liver—liver cancer	0.000378	0.00776	CbGeAlD
Ponatinib—ABCB11—liver—liver cancer	0.000369	0.00758	CbGeAlD
Ponatinib—FGFR2—liver—liver cancer	0.000359	0.00737	CbGeAlD
Ponatinib—TEK—liver—liver cancer	0.000344	0.00707	CbGeAlD
Ponatinib—ABL1—Daunorubicin—Epirubicin—liver cancer	0.000321	0.173	CbGdCrCtD
Ponatinib—ABL1—Doxorubicin—Epirubicin—liver cancer	0.000321	0.173	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Epirubicin—liver cancer	0.000321	0.173	CbGdCrCtD
Ponatinib—PDGFRA—liver—liver cancer	0.000312	0.0064	CbGeAlD
Ponatinib—SRC—liver—liver cancer	0.000306	0.00628	CbGeAlD
Ponatinib—ABL1—Epirubicin—Doxorubicin—liver cancer	0.000297	0.16	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Doxorubicin—liver cancer	0.000297	0.16	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—liver cancer	0.000297	0.16	CbGdCrCtD
Ponatinib—KDR—liver—liver cancer	0.000282	0.00578	CbGeAlD
Ponatinib—KIT—liver—liver cancer	0.000249	0.00512	CbGeAlD
Ponatinib—ABL1—liver—liver cancer	0.000217	0.00446	CbGeAlD
Ponatinib—Creatinine increased—Epirubicin—liver cancer	0.000175	0.00251	CcSEcCtD
Ponatinib—Bone pain—Epirubicin—liver cancer	0.000174	0.00249	CcSEcCtD
Ponatinib—Cough—Sorafenib—liver cancer	0.000172	0.00246	CcSEcCtD
Ponatinib—Hypertension—Sorafenib—liver cancer	0.00017	0.00244	CcSEcCtD
Ponatinib—Blood uric acid increased—Epirubicin—liver cancer	0.000169	0.00243	CcSEcCtD
Ponatinib—Cellulitis—Doxorubicin—liver cancer	0.000169	0.00243	CcSEcCtD
Ponatinib—Musculoskeletal pain—Epirubicin—liver cancer	0.000168	0.00241	CcSEcCtD
Ponatinib—Neck pain—Epirubicin—liver cancer	0.000168	0.00241	CcSEcCtD
Ponatinib—Hypocalcaemia—Doxorubicin—liver cancer	0.000168	0.00241	CcSEcCtD
Ponatinib—Myalgia—Sorafenib—liver cancer	0.000168	0.0024	CcSEcCtD
Ponatinib—Arthralgia—Sorafenib—liver cancer	0.000168	0.0024	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000166	0.00239	CcSEcCtD
Ponatinib—Phosphatase alkaline increased—Epirubicin—liver cancer	0.000166	0.00239	CcSEcCtD
Ponatinib—Pulmonary embolism—Epirubicin—liver cancer	0.000166	0.00239	CcSEcCtD
Ponatinib—Hyperuricaemia—Doxorubicin—liver cancer	0.000166	0.00238	CcSEcCtD
Ponatinib—Dry mouth—Sorafenib—liver cancer	0.000164	0.00235	CcSEcCtD
Ponatinib—Blood bilirubin increased—Doxorubicin—liver cancer	0.000163	0.00233	CcSEcCtD
Ponatinib—Creatinine increased—Doxorubicin—liver cancer	0.000162	0.00232	CcSEcCtD
Ponatinib—Influenza like illness—Epirubicin—liver cancer	0.000162	0.00232	CcSEcCtD
Ponatinib—Bone pain—Doxorubicin—liver cancer	0.000161	0.0023	CcSEcCtD
Ponatinib—Infection—Sorafenib—liver cancer	0.00016	0.00229	CcSEcCtD
Ponatinib—Skin exfoliation—Epirubicin—liver cancer	0.000159	0.00228	CcSEcCtD
Ponatinib—Fluid retention—Epirubicin—liver cancer	0.000158	0.00226	CcSEcCtD
Ponatinib—Nervous system disorder—Sorafenib—liver cancer	0.000158	0.00226	CcSEcCtD
Ponatinib—Thrombocytopenia—Sorafenib—liver cancer	0.000157	0.00226	CcSEcCtD
Ponatinib—Blood uric acid increased—Doxorubicin—liver cancer	0.000157	0.00225	CcSEcCtD
Ponatinib—Neuropathy—Epirubicin—liver cancer	0.000156	0.00224	CcSEcCtD
Ponatinib—Skin disorder—Sorafenib—liver cancer	0.000156	0.00224	CcSEcCtD
Ponatinib—Musculoskeletal pain—Doxorubicin—liver cancer	0.000156	0.00223	CcSEcCtD
Ponatinib—Neck pain—Doxorubicin—liver cancer	0.000156	0.00223	CcSEcCtD
Ponatinib—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.000154	0.00221	CcSEcCtD
Ponatinib—Pulmonary embolism—Doxorubicin—liver cancer	0.000154	0.00221	CcSEcCtD
Ponatinib—Dry eye—Epirubicin—liver cancer	0.000154	0.0022	CcSEcCtD
Ponatinib—Ecchymosis—Epirubicin—liver cancer	0.00015	0.00216	CcSEcCtD
Ponatinib—Influenza like illness—Doxorubicin—liver cancer	0.000149	0.00214	CcSEcCtD
Ponatinib—Skin exfoliation—Doxorubicin—liver cancer	0.000147	0.00211	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000146	0.0021	CcSEcCtD
Ponatinib—Fluid retention—Doxorubicin—liver cancer	0.000146	0.0021	CcSEcCtD
Ponatinib—ABCB1—embryo—liver cancer	0.000146	0.003	CbGeAlD
Ponatinib—Neuropathy—Doxorubicin—liver cancer	0.000145	0.00207	CcSEcCtD
Ponatinib—Sepsis—Epirubicin—liver cancer	0.000144	0.00207	CcSEcCtD
Ponatinib—Dyspnoea—Sorafenib—liver cancer	0.000143	0.00205	CcSEcCtD
Ponatinib—Dry eye—Doxorubicin—liver cancer	0.000142	0.00204	CcSEcCtD
Ponatinib—Dyspepsia—Sorafenib—liver cancer	0.000141	0.00203	CcSEcCtD
Ponatinib—CYP2C8—liver—liver cancer	0.000141	0.00289	CbGeAlD
Ponatinib—Decreased appetite—Sorafenib—liver cancer	0.00014	0.002	CcSEcCtD
Ponatinib—Ecchymosis—Doxorubicin—liver cancer	0.000139	0.002	CcSEcCtD
Ponatinib—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.000139	0.00199	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Sorafenib—liver cancer	0.000139	0.00199	CcSEcCtD
Ponatinib—Fatigue—Sorafenib—liver cancer	0.000138	0.00199	CcSEcCtD
Ponatinib—Pain—Sorafenib—liver cancer	0.000137	0.00197	CcSEcCtD
Ponatinib—Constipation—Sorafenib—liver cancer	0.000137	0.00197	CcSEcCtD
Ponatinib—ABCG2—liver—liver cancer	0.000137	0.00281	CbGeAlD
Ponatinib—Sepsis—Doxorubicin—liver cancer	0.000134	0.00192	CcSEcCtD
Ponatinib—Cardiac failure congestive—Epirubicin—liver cancer	0.000133	0.00191	CcSEcCtD
Ponatinib—Gastrointestinal pain—Sorafenib—liver cancer	0.000131	0.00188	CcSEcCtD
Ponatinib—Hot flush—Epirubicin—liver cancer	0.000129	0.00185	CcSEcCtD
Ponatinib—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000128	0.00184	CcSEcCtD
Ponatinib—Dermatitis exfoliative—Epirubicin—liver cancer	0.000128	0.00184	CcSEcCtD
Ponatinib—Menopausal symptoms—Epirubicin—liver cancer	0.000128	0.00184	CcSEcCtD
Ponatinib—CYP3A5—liver—liver cancer	0.000127	0.00261	CbGeAlD
Ponatinib—Abdominal pain—Sorafenib—liver cancer	0.000127	0.00182	CcSEcCtD
Ponatinib—Body temperature increased—Sorafenib—liver cancer	0.000127	0.00182	CcSEcCtD
Ponatinib—Cardiac failure—Epirubicin—liver cancer	0.000124	0.00177	CcSEcCtD
Ponatinib—Cerebrovascular accident—Epirubicin—liver cancer	0.000123	0.00177	CcSEcCtD
Ponatinib—Lethargy—Epirubicin—liver cancer	0.000123	0.00177	CcSEcCtD
Ponatinib—Cardiac failure congestive—Doxorubicin—liver cancer	0.000123	0.00177	CcSEcCtD
Ponatinib—Hyponatraemia—Epirubicin—liver cancer	0.000121	0.00174	CcSEcCtD
Ponatinib—Pain in extremity—Epirubicin—liver cancer	0.000121	0.00173	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000121	0.00173	CcSEcCtD
Ponatinib—Hot flush—Doxorubicin—liver cancer	0.000119	0.00171	CcSEcCtD
Ponatinib—Migraine—Epirubicin—liver cancer	0.000119	0.0017	CcSEcCtD
Ponatinib—Menopausal symptoms—Doxorubicin—liver cancer	0.000118	0.0017	CcSEcCtD
Ponatinib—Dermatitis exfoliative—Doxorubicin—liver cancer	0.000118	0.0017	CcSEcCtD
Ponatinib—Face oedema—Epirubicin—liver cancer	0.000117	0.00167	CcSEcCtD
Ponatinib—Asthenia—Sorafenib—liver cancer	0.000115	0.00165	CcSEcCtD
Ponatinib—Cardiac failure—Doxorubicin—liver cancer	0.000114	0.00164	CcSEcCtD
Ponatinib—Lethargy—Doxorubicin—liver cancer	0.000114	0.00164	CcSEcCtD
Ponatinib—Cerebrovascular accident—Doxorubicin—liver cancer	0.000114	0.00164	CcSEcCtD
Ponatinib—Pruritus—Sorafenib—liver cancer	0.000114	0.00163	CcSEcCtD
Ponatinib—Blood creatinine increased—Epirubicin—liver cancer	0.000113	0.00162	CcSEcCtD
Ponatinib—Dehydration—Epirubicin—liver cancer	0.000112	0.00161	CcSEcCtD
Ponatinib—Hyponatraemia—Doxorubicin—liver cancer	0.000112	0.00161	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000112	0.0016	CcSEcCtD
Ponatinib—Pain in extremity—Doxorubicin—liver cancer	0.000112	0.0016	CcSEcCtD
Ponatinib—Dry skin—Epirubicin—liver cancer	0.000111	0.00159	CcSEcCtD
Ponatinib—Migraine—Doxorubicin—liver cancer	0.00011	0.00158	CcSEcCtD
Ponatinib—Hypokalaemia—Epirubicin—liver cancer	0.00011	0.00158	CcSEcCtD
Ponatinib—Diarrhoea—Sorafenib—liver cancer	0.00011	0.00158	CcSEcCtD
Ponatinib—Breast disorder—Epirubicin—liver cancer	0.000109	0.00156	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000109	0.00156	CcSEcCtD
Ponatinib—Nasopharyngitis—Epirubicin—liver cancer	0.000108	0.00155	CcSEcCtD
Ponatinib—Face oedema—Doxorubicin—liver cancer	0.000108	0.00155	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000107	0.00153	CcSEcCtD
Ponatinib—Dizziness—Sorafenib—liver cancer	0.000106	0.00152	CcSEcCtD
Ponatinib—Abdominal distension—Epirubicin—liver cancer	0.000105	0.00151	CcSEcCtD
Ponatinib—Blood creatinine increased—Doxorubicin—liver cancer	0.000105	0.0015	CcSEcCtD
Ponatinib—Dehydration—Doxorubicin—liver cancer	0.000104	0.00149	CcSEcCtD
Ponatinib—Dry skin—Doxorubicin—liver cancer	0.000102	0.00147	CcSEcCtD
Ponatinib—Pancreatitis—Epirubicin—liver cancer	0.000102	0.00147	CcSEcCtD
Ponatinib—Vomiting—Sorafenib—liver cancer	0.000102	0.00146	CcSEcCtD
Ponatinib—Hypokalaemia—Doxorubicin—liver cancer	0.000102	0.00146	CcSEcCtD
Ponatinib—Angina pectoris—Epirubicin—liver cancer	0.000102	0.00146	CcSEcCtD
Ponatinib—Rash—Sorafenib—liver cancer	0.000101	0.00145	CcSEcCtD
Ponatinib—Dermatitis—Sorafenib—liver cancer	0.000101	0.00145	CcSEcCtD
Ponatinib—Breast disorder—Doxorubicin—liver cancer	0.000101	0.00145	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000101	0.00144	CcSEcCtD
Ponatinib—Headache—Sorafenib—liver cancer	0.000101	0.00144	CcSEcCtD
Ponatinib—Nasopharyngitis—Doxorubicin—liver cancer	9.99e-05	0.00143	CcSEcCtD
Ponatinib—Pancytopenia—Epirubicin—liver cancer	9.91e-05	0.00142	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Doxorubicin—liver cancer	9.86e-05	0.00141	CcSEcCtD
Ponatinib—Neutropenia—Epirubicin—liver cancer	9.76e-05	0.0014	CcSEcCtD
Ponatinib—Abdominal distension—Doxorubicin—liver cancer	9.72e-05	0.00139	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Epirubicin—liver cancer	9.7e-05	0.00139	CcSEcCtD
Ponatinib—CYP3A4—liver—liver cancer	9.54e-05	0.00196	CbGeAlD
Ponatinib—Nausea—Sorafenib—liver cancer	9.54e-05	0.00137	CcSEcCtD
Ponatinib—Pancreatitis—Doxorubicin—liver cancer	9.47e-05	0.00136	CcSEcCtD
Ponatinib—Weight decreased—Epirubicin—liver cancer	9.44e-05	0.00135	CcSEcCtD
Ponatinib—Hyperglycaemia—Epirubicin—liver cancer	9.42e-05	0.00135	CcSEcCtD
Ponatinib—Angina pectoris—Doxorubicin—liver cancer	9.41e-05	0.00135	CcSEcCtD
Ponatinib—CYP2D6—liver—liver cancer	9.39e-05	0.00193	CbGeAlD
Ponatinib—Pneumonia—Epirubicin—liver cancer	9.36e-05	0.00134	CcSEcCtD
Ponatinib—Infestation NOS—Epirubicin—liver cancer	9.31e-05	0.00133	CcSEcCtD
Ponatinib—Infestation—Epirubicin—liver cancer	9.31e-05	0.00133	CcSEcCtD
Ponatinib—Pancytopenia—Doxorubicin—liver cancer	9.17e-05	0.00132	CcSEcCtD
Ponatinib—Neuropathy peripheral—Epirubicin—liver cancer	9.12e-05	0.00131	CcSEcCtD
Ponatinib—Jaundice—Epirubicin—liver cancer	9.07e-05	0.0013	CcSEcCtD
Ponatinib—Stomatitis—Epirubicin—liver cancer	9.07e-05	0.0013	CcSEcCtD
Ponatinib—Urinary tract infection—Epirubicin—liver cancer	9.05e-05	0.0013	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—liver cancer	9.03e-05	0.0013	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—liver cancer	8.98e-05	0.00129	CcSEcCtD
Ponatinib—Hepatobiliary disease—Epirubicin—liver cancer	8.8e-05	0.00126	CcSEcCtD
Ponatinib—Epistaxis—Epirubicin—liver cancer	8.78e-05	0.00126	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—liver cancer	8.74e-05	0.00125	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—liver cancer	8.71e-05	0.00125	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—liver cancer	8.66e-05	0.00124	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—liver cancer	8.61e-05	0.00123	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—liver cancer	8.61e-05	0.00123	CcSEcCtD
Ponatinib—Imatinib—ALB—liver cancer	8.53e-05	0.0235	CrCbGaD
Ponatinib—Neuropathy peripheral—Doxorubicin—liver cancer	8.44e-05	0.00121	CcSEcCtD
Ponatinib—Haemoglobin—Epirubicin—liver cancer	8.4e-05	0.0012	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—liver cancer	8.39e-05	0.0012	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—liver cancer	8.39e-05	0.0012	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—liver cancer	8.37e-05	0.0012	CcSEcCtD
Ponatinib—Haemorrhage—Epirubicin—liver cancer	8.35e-05	0.0012	CcSEcCtD
Ponatinib—Hypoaesthesia—Epirubicin—liver cancer	8.31e-05	0.00119	CcSEcCtD
Ponatinib—Oedema peripheral—Epirubicin—liver cancer	8.23e-05	0.00118	CcSEcCtD
Ponatinib—Connective tissue disorder—Epirubicin—liver cancer	8.21e-05	0.00118	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—liver cancer	8.14e-05	0.00117	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—liver cancer	8.12e-05	0.00116	CcSEcCtD
Ponatinib—Visual impairment—Epirubicin—liver cancer	8.05e-05	0.00115	CcSEcCtD
Ponatinib—Eye disorder—Epirubicin—liver cancer	7.81e-05	0.00112	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—liver cancer	7.77e-05	0.00111	CcSEcCtD
Ponatinib—Flushing—Epirubicin—liver cancer	7.75e-05	0.00111	CcSEcCtD
Ponatinib—Cardiac disorder—Epirubicin—liver cancer	7.75e-05	0.00111	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—liver cancer	7.73e-05	0.00111	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—liver cancer	7.69e-05	0.0011	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—liver cancer	7.62e-05	0.00109	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—liver cancer	7.6e-05	0.00109	CcSEcCtD
Ponatinib—Angiopathy—Epirubicin—liver cancer	7.58e-05	0.00109	CcSEcCtD
Ponatinib—Mediastinal disorder—Epirubicin—liver cancer	7.53e-05	0.00108	CcSEcCtD
Ponatinib—Chills—Epirubicin—liver cancer	7.5e-05	0.00107	CcSEcCtD
Ponatinib—Arrhythmia—Epirubicin—liver cancer	7.46e-05	0.00107	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—liver cancer	7.45e-05	0.00107	CcSEcCtD
Ponatinib—Alopecia—Epirubicin—liver cancer	7.38e-05	0.00106	CcSEcCtD
Ponatinib—Mental disorder—Epirubicin—liver cancer	7.32e-05	0.00105	CcSEcCtD
Ponatinib—Malnutrition—Epirubicin—liver cancer	7.27e-05	0.00104	CcSEcCtD
Ponatinib—Erythema—Epirubicin—liver cancer	7.27e-05	0.00104	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—liver cancer	7.22e-05	0.00104	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—liver cancer	7.17e-05	0.00103	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—liver cancer	7.17e-05	0.00103	CcSEcCtD
Ponatinib—Back pain—Epirubicin—liver cancer	7.03e-05	0.00101	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—liver cancer	7.01e-05	0.00101	CcSEcCtD
Ponatinib—Muscle spasms—Epirubicin—liver cancer	6.99e-05	0.001	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—liver cancer	6.97e-05	0.000999	CcSEcCtD
Ponatinib—Chills—Doxorubicin—liver cancer	6.94e-05	0.000995	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—liver cancer	6.91e-05	0.00099	CcSEcCtD
Ponatinib—Vision blurred—Epirubicin—liver cancer	6.85e-05	0.000983	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—liver cancer	6.83e-05	0.00098	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—liver cancer	6.77e-05	0.000971	CcSEcCtD
Ponatinib—ABCB1—liver—liver cancer	6.75e-05	0.00139	CbGeAlD
Ponatinib—Malnutrition—Doxorubicin—liver cancer	6.73e-05	0.000965	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—liver cancer	6.73e-05	0.000965	CcSEcCtD
Ponatinib—Anaemia—Epirubicin—liver cancer	6.72e-05	0.000964	CcSEcCtD
Ponatinib—Leukopenia—Epirubicin—liver cancer	6.51e-05	0.000934	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—liver cancer	6.51e-05	0.000933	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—liver cancer	6.47e-05	0.000928	CcSEcCtD
Ponatinib—Cough—Epirubicin—liver cancer	6.35e-05	0.00091	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—liver cancer	6.34e-05	0.000909	CcSEcCtD
Ponatinib—Hypertension—Epirubicin—liver cancer	6.28e-05	0.0009	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—liver cancer	6.22e-05	0.000892	CcSEcCtD
Ponatinib—Arthralgia—Epirubicin—liver cancer	6.19e-05	0.000888	CcSEcCtD
Ponatinib—Myalgia—Epirubicin—liver cancer	6.19e-05	0.000888	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	6.15e-05	0.000882	CcSEcCtD
Ponatinib—Dry mouth—Epirubicin—liver cancer	6.06e-05	0.000868	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—liver cancer	6.02e-05	0.000864	CcSEcCtD
Ponatinib—Oedema—Epirubicin—liver cancer	5.94e-05	0.000851	CcSEcCtD
Ponatinib—Infection—Epirubicin—liver cancer	5.9e-05	0.000846	CcSEcCtD
Ponatinib—Cough—Doxorubicin—liver cancer	5.87e-05	0.000842	CcSEcCtD
Ponatinib—Nervous system disorder—Epirubicin—liver cancer	5.82e-05	0.000835	CcSEcCtD
Ponatinib—Thrombocytopenia—Epirubicin—liver cancer	5.81e-05	0.000833	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—liver cancer	5.81e-05	0.000833	CcSEcCtD
Ponatinib—Skin disorder—Epirubicin—liver cancer	5.77e-05	0.000827	CcSEcCtD
Ponatinib—Hyperhidrosis—Epirubicin—liver cancer	5.74e-05	0.000823	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—liver cancer	5.73e-05	0.000822	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—liver cancer	5.73e-05	0.000822	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	5.69e-05	0.000816	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—liver cancer	5.6e-05	0.000803	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—liver cancer	5.49e-05	0.000788	CcSEcCtD
Ponatinib—Infection—Doxorubicin—liver cancer	5.46e-05	0.000782	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Epirubicin—liver cancer	5.41e-05	0.000775	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—liver cancer	5.39e-05	0.000772	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—liver cancer	5.38e-05	0.000771	CcSEcCtD
Ponatinib—Insomnia—Epirubicin—liver cancer	5.37e-05	0.00077	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—liver cancer	5.33e-05	0.000765	CcSEcCtD
Ponatinib—Paraesthesia—Epirubicin—liver cancer	5.33e-05	0.000764	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—liver cancer	5.31e-05	0.000761	CcSEcCtD
Ponatinib—Dyspnoea—Epirubicin—liver cancer	5.29e-05	0.000759	CcSEcCtD
Ponatinib—Dyspepsia—Epirubicin—liver cancer	5.22e-05	0.000749	CcSEcCtD
Ponatinib—Decreased appetite—Epirubicin—liver cancer	5.16e-05	0.00074	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Epirubicin—liver cancer	5.12e-05	0.000735	CcSEcCtD
Ponatinib—Fatigue—Epirubicin—liver cancer	5.12e-05	0.000734	CcSEcCtD
Ponatinib—Pain—Epirubicin—liver cancer	5.08e-05	0.000728	CcSEcCtD
Ponatinib—Constipation—Epirubicin—liver cancer	5.08e-05	0.000728	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—liver cancer	5e-05	0.000718	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—liver cancer	4.97e-05	0.000712	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—liver cancer	4.93e-05	0.000707	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—liver cancer	4.9e-05	0.000702	CcSEcCtD
Ponatinib—Gastrointestinal pain—Epirubicin—liver cancer	4.85e-05	0.000696	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—liver cancer	4.83e-05	0.000693	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—liver cancer	4.77e-05	0.000685	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—liver cancer	4.74e-05	0.00068	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—liver cancer	4.73e-05	0.000679	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—liver cancer	4.7e-05	0.000673	CcSEcCtD
Ponatinib—Pain—Doxorubicin—liver cancer	4.7e-05	0.000673	CcSEcCtD
Ponatinib—Abdominal pain—Epirubicin—liver cancer	4.69e-05	0.000673	CcSEcCtD
Ponatinib—Body temperature increased—Epirubicin—liver cancer	4.69e-05	0.000673	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—liver cancer	4.49e-05	0.000644	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—liver cancer	4.34e-05	0.000623	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—liver cancer	4.34e-05	0.000623	CcSEcCtD
Ponatinib—Asthenia—Epirubicin—liver cancer	4.26e-05	0.000611	CcSEcCtD
Ponatinib—Pruritus—Epirubicin—liver cancer	4.2e-05	0.000602	CcSEcCtD
Ponatinib—Diarrhoea—Epirubicin—liver cancer	4.06e-05	0.000582	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—liver cancer	3.94e-05	0.000565	CcSEcCtD
Ponatinib—Dizziness—Epirubicin—liver cancer	3.93e-05	0.000563	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—liver cancer	3.89e-05	0.000557	CcSEcCtD
Ponatinib—Vomiting—Epirubicin—liver cancer	3.77e-05	0.000541	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—liver cancer	3.76e-05	0.000539	CcSEcCtD
Ponatinib—Rash—Epirubicin—liver cancer	3.74e-05	0.000537	CcSEcCtD
Ponatinib—Dermatitis—Epirubicin—liver cancer	3.74e-05	0.000536	CcSEcCtD
Ponatinib—Headache—Epirubicin—liver cancer	3.72e-05	0.000533	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—liver cancer	3.63e-05	0.000521	CcSEcCtD
Ponatinib—Nausea—Epirubicin—liver cancer	3.53e-05	0.000506	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—liver cancer	3.49e-05	0.000501	CcSEcCtD
Ponatinib—Rash—Doxorubicin—liver cancer	3.46e-05	0.000497	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—liver cancer	3.46e-05	0.000496	CcSEcCtD
Ponatinib—Headache—Doxorubicin—liver cancer	3.44e-05	0.000493	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—liver cancer	3.26e-05	0.000468	CcSEcCtD
Ponatinib—ABCB1—Metabolism—GSTP1—liver cancer	1.32e-06	1.27e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP1A1—liver cancer	1.32e-06	1.27e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CDKN1A—liver cancer	1.32e-06	1.27e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—STAT3—liver cancer	1.32e-06	1.27e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CDKN1B—liver cancer	1.31e-06	1.26e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CDKN1A—liver cancer	1.31e-06	1.26e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—HMOX1—liver cancer	1.31e-06	1.25e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—liver cancer	1.3e-06	1.25e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK8—liver cancer	1.3e-06	1.24e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—AKT1—liver cancer	1.29e-06	1.24e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK8—liver cancer	1.29e-06	1.24e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—liver cancer	1.29e-06	1.24e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—liver cancer	1.28e-06	1.23e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CB—liver cancer	1.28e-06	1.23e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—liver cancer	1.28e-06	1.23e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK8—liver cancer	1.28e-06	1.23e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APC—liver cancer	1.28e-06	1.22e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CG—liver cancer	1.28e-06	1.22e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—liver cancer	1.28e-06	1.22e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—PIK3CA—liver cancer	1.27e-06	1.22e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—STAT3—liver cancer	1.27e-06	1.22e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PIK3CA—liver cancer	1.27e-06	1.22e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CD—liver cancer	1.27e-06	1.22e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—liver cancer	1.27e-06	1.22e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—liver cancer	1.27e-06	1.21e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—PIK3CA—liver cancer	1.27e-06	1.21e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1B—liver cancer	1.27e-06	1.21e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—liver cancer	1.26e-06	1.21e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SERPINE1—liver cancer	1.25e-06	1.2e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—STAT3—liver cancer	1.25e-06	1.2e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTP1—liver cancer	1.25e-06	1.2e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—liver cancer	1.24e-06	1.19e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—liver cancer	1.24e-06	1.19e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—liver cancer	1.24e-06	1.19e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CASP3—liver cancer	1.24e-06	1.19e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CTNNB1—liver cancer	1.24e-06	1.19e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2—liver cancer	1.24e-06	1.19e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—liver cancer	1.23e-06	1.18e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MTHFR—liver cancer	1.23e-06	1.18e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—liver cancer	1.23e-06	1.18e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—HMOX1—liver cancer	1.23e-06	1.18e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—liver cancer	1.23e-06	1.18e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—STAT3—liver cancer	1.22e-06	1.17e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTM1—liver cancer	1.22e-06	1.17e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HPGDS—liver cancer	1.21e-06	1.16e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARA—liver cancer	1.21e-06	1.16e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CDKN1A—liver cancer	1.21e-06	1.16e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—liver cancer	1.21e-06	1.16e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—JUN—liver cancer	1.2e-06	1.15e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—BRAF—liver cancer	1.2e-06	1.15e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CG—liver cancer	1.2e-06	1.15e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—liver cancer	1.2e-06	1.15e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CTNNB1—liver cancer	1.2e-06	1.15e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—liver cancer	1.19e-06	1.14e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—liver cancer	1.19e-06	1.14e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STAT3—liver cancer	1.18e-06	1.14e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—liver cancer	1.18e-06	1.13e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STAT3—liver cancer	1.18e-06	1.13e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—liver cancer	1.18e-06	1.13e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—liver cancer	1.18e-06	1.13e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—liver cancer	1.18e-06	1.13e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—liver cancer	1.18e-06	1.13e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TGFB1—liver cancer	1.18e-06	1.13e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—liver cancer	1.18e-06	1.13e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—liver cancer	1.18e-06	1.13e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—liver cancer	1.17e-06	1.13e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—liver cancer	1.17e-06	1.12e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—liver cancer	1.17e-06	1.12e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—STAT3—liver cancer	1.17e-06	1.12e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—liver cancer	1.17e-06	1.12e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1A—liver cancer	1.17e-06	1.12e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—liver cancer	1.16e-06	1.11e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFB1—liver cancer	1.16e-06	1.11e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARG—liver cancer	1.16e-06	1.11e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP1A1—liver cancer	1.15e-06	1.11e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—liver cancer	1.15e-06	1.1e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTM1—liver cancer	1.15e-06	1.1e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK8—liver cancer	1.14e-06	1.09e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—liver cancer	1.13e-06	1.09e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—liver cancer	1.13e-06	1.09e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RAF1—liver cancer	1.13e-06	1.09e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFB1—liver cancer	1.13e-06	1.08e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—liver cancer	1.13e-06	1.08e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—liver cancer	1.12e-06	1.08e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CD—liver cancer	1.12e-06	1.08e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—liver cancer	1.12e-06	1.07e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SERPINE1—liver cancer	1.11e-06	1.06e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CB—liver cancer	1.11e-06	1.06e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MTOR—liver cancer	1.11e-06	1.06e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—liver cancer	1.1e-06	1.05e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFB1—liver cancer	1.1e-06	1.05e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—liver cancer	1.1e-06	1.05e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFB1—liver cancer	1.1e-06	1.05e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—liver cancer	1.09e-06	1.05e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—liver cancer	1.09e-06	1.04e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.09e-06	1.04e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—liver cancer	1.09e-06	1.04e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP1A1—liver cancer	1.09e-06	1.04e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PSMA4—liver cancer	1.08e-06	1.04e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PSMD10—liver cancer	1.08e-06	1.04e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—liver cancer	1.08e-06	1.04e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—liver cancer	1.08e-06	1.03e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—liver cancer	1.07e-06	1.03e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARA—liver cancer	1.06e-06	1.01e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CD—liver cancer	1.05e-06	1.01e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—liver cancer	1.05e-06	1.01e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GOT2—liver cancer	1.05e-06	1.01e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—liver cancer	1.05e-06	1e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—liver cancer	1.04e-06	9.99e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—liver cancer	1.04e-06	9.99e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ALB—liver cancer	1.04e-06	9.96e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—liver cancer	1.04e-06	9.96e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—liver cancer	1.04e-06	9.94e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1B—liver cancer	1.04e-06	9.94e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CG—liver cancer	1.04e-06	9.94e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—liver cancer	1.03e-06	9.91e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—liver cancer	1.02e-06	9.75e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—liver cancer	1.02e-06	9.74e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—liver cancer	1.02e-06	9.73e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—liver cancer	1.01e-06	9.72e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—liver cancer	1.01e-06	9.71e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—liver cancer	1e-06	9.63e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—liver cancer	1e-06	9.62e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—liver cancer	1e-06	9.61e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RAF1—liver cancer	1e-06	9.61e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFB1—liver cancer	1e-06	9.59e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARG—liver cancer	1e-06	9.59e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARA—liver cancer	9.94e-07	9.53e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—liver cancer	9.9e-07	9.48e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2E1—liver cancer	9.89e-07	9.48e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—JUN—liver cancer	9.87e-07	9.46e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—liver cancer	9.85e-07	9.44e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CTNNB1—liver cancer	9.8e-07	9.39e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MTOR—liver cancer	9.78e-07	9.38e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CB—liver cancer	9.78e-07	9.38e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—liver cancer	9.7e-07	9.3e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—liver cancer	9.68e-07	9.28e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFB1—liver cancer	9.66e-07	9.26e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—liver cancer	9.65e-07	9.25e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—liver cancer	9.64e-07	9.24e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—liver cancer	9.62e-07	9.22e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—liver cancer	9.61e-07	9.21e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1A—liver cancer	9.57e-07	9.18e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—liver cancer	9.52e-07	9.13e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—liver cancer	9.34e-07	8.96e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK8—liver cancer	9.34e-07	8.96e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—liver cancer	9.32e-07	8.93e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—liver cancer	9.27e-07	8.89e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—liver cancer	9.27e-07	8.89e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYCS—liver cancer	9.26e-07	8.87e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—liver cancer	9.23e-07	8.85e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—liver cancer	9.23e-07	8.84e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1B—liver cancer	9.18e-07	8.8e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CB—liver cancer	9.17e-07	8.79e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CD—liver cancer	9.12e-07	8.74e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—liver cancer	9.11e-07	8.73e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GOT1—liver cancer	9.08e-07	8.71e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GGT1—liver cancer	9.08e-07	8.71e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—liver cancer	9.04e-07	8.66e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CG—liver cancer	9.04e-07	8.66e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—liver cancer	9.02e-07	8.64e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ALB—liver cancer	9e-07	8.63e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—liver cancer	9e-07	8.63e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—liver cancer	8.99e-07	8.61e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—liver cancer	8.95e-07	8.58e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—liver cancer	8.9e-07	8.53e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—liver cancer	8.88e-07	8.51e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—liver cancer	8.76e-07	8.4e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—JUN—liver cancer	8.74e-07	8.38e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARG—liver cancer	8.72e-07	8.36e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—liver cancer	8.72e-07	8.36e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CTNNB1—liver cancer	8.67e-07	8.31e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—liver cancer	8.64e-07	8.29e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—liver cancer	8.63e-07	8.27e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—liver cancer	8.62e-07	8.26e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—liver cancer	8.54e-07	8.19e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—liver cancer	8.54e-07	8.18e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—liver cancer	8.52e-07	8.17e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—liver cancer	8.52e-07	8.16e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CG—liver cancer	8.51e-07	8.16e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—liver cancer	8.51e-07	8.16e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—liver cancer	8.5e-07	8.15e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1A—liver cancer	8.47e-07	8.12e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—liver cancer	8.27e-07	7.93e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK8—liver cancer	8.27e-07	7.93e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—liver cancer	8.25e-07	7.91e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—liver cancer	8.22e-07	7.88e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARG—liver cancer	8.22e-07	7.88e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—liver cancer	8.19e-07	7.85e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—liver cancer	8.17e-07	7.83e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTP1—liver cancer	8.16e-07	7.82e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HMOX1—liver cancer	8.05e-07	7.71e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—liver cancer	8.04e-07	7.71e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—liver cancer	7.95e-07	7.62e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CB—liver cancer	7.95e-07	7.62e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CD—liver cancer	7.94e-07	7.61e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—liver cancer	7.94e-07	7.61e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFB1—liver cancer	7.92e-07	7.59e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—liver cancer	7.88e-07	7.55e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—liver cancer	7.86e-07	7.53e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ALB—liver cancer	7.84e-07	7.52e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—liver cancer	7.81e-07	7.48e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—liver cancer	7.64e-07	7.32e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—liver cancer	7.63e-07	7.32e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—liver cancer	7.61e-07	7.3e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—liver cancer	7.61e-07	7.29e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—liver cancer	7.56e-07	7.25e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—liver cancer	7.54e-07	7.23e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—liver cancer	7.54e-07	7.22e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTM1—liver cancer	7.5e-07	7.19e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CD—liver cancer	7.48e-07	7.17e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALB—liver cancer	7.39e-07	7.08e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—liver cancer	7.33e-07	7.03e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—liver cancer	7.28e-07	6.98e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1A1—liver cancer	7.11e-07	6.81e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—liver cancer	7.03e-07	6.73e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFB1—liver cancer	7.01e-07	6.72e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—liver cancer	6.96e-07	6.67e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CB—liver cancer	6.92e-07	6.64e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—liver cancer	6.74e-07	6.46e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—liver cancer	6.72e-07	6.44e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—liver cancer	6.63e-07	6.35e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CB—liver cancer	6.52e-07	6.25e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—liver cancer	6.52e-07	6.25e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARA—liver cancer	6.5e-07	6.23e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—liver cancer	6.49e-07	6.22e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—liver cancer	6.38e-07	6.11e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—liver cancer	6.23e-07	5.98e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—liver cancer	5.97e-07	5.72e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—liver cancer	5.96e-07	5.72e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—liver cancer	5.77e-07	5.53e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—liver cancer	5.59e-07	5.36e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CG—liver cancer	5.57e-07	5.34e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—liver cancer	5.52e-07	5.29e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—liver cancer	5.5e-07	5.28e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARG—liver cancer	5.37e-07	5.15e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—liver cancer	5.28e-07	5.06e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CD—liver cancer	4.89e-07	4.69e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—liver cancer	4.87e-07	4.67e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—liver cancer	4.84e-07	4.64e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALB—liver cancer	4.83e-07	4.63e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—liver cancer	4.57e-07	4.38e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CB—liver cancer	4.27e-07	4.09e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—liver cancer	4.22e-07	4.05e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—liver cancer	3.98e-07	3.81e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—liver cancer	3.96e-07	3.79e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—liver cancer	3.45e-07	3.3e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—liver cancer	3.25e-07	3.11e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—liver cancer	2.6e-07	2.49e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—liver cancer	2.12e-07	2.04e-06	CbGpPWpGaD
